Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk
DUO-E is a global, randomised, double-blind, Phase III study investigating the efficacy and safety of the addition of IMFINZI (durvalumab) followed by IMFINZI® (durvalumab) with or without LYNPARZA® (olaparib) to carboplatin and paclitaxel for newly diagnosed advanced/recurrent endometrial cancer across all histologies, including carcinosarcomas (except sarcomas).
Adapted from Westin SN, et al; 2024
OS in patients with pMMR arEC (80% of ITT population)
Duration of response in patients with pMMR arEC
ORR in patients with pMMR arEC
Broadening horizons for your dMMR arEC patients with more time progression-free (p-value not tested)
Adapted from Westin SN, et al; 2024.
OS in patients with dMMR arEC (20% of ITT population)
Duration of response in patients with dMMR arEC
ORR in patients with pMMR arEC
The IMFINZI® + CP with or without LYNPARZA® regimens were generally well tolerated and adverse events remain consistent with the established safety profiles of the individual components.
Adverse events of special interest
Immune-mediated adverse reactions are special warnings for Imfinzi. MDS/AML and pneumonitis are special warnings for Lynparza. Pure red cell aplasia and autoimmune haemolytic anaemia are special warnings for the Lynparza and Imfinzi regimen. Please refer to the relevant Summary of Product Characteristics before prescribing to help minimise the risks associated with the use of the combination
No cases of myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML)1
* MDS/AML and new primary malignancies include AEs from first dose of investigational product (durvalumab/placebo or olaparib/placebo) until the end of the study (includes cases reported beyond the safety follow-up period). †Excludes one event of basal cell carcinoma. ‡Grouped term; includes pneumonitis, bronchiolitis and interstitial lung disease.
PRCA and/or AIHA have been reported with the LYNPARZA® + IMFINZI® Regimen
In the DUO-E study:
AE, adverse events; AIHA, autoimmune haemolytic anaemia; AML, acute myeloid leukaemia; CP, carboplatin/paclitaxel; MDS, myelodysplastic syndrome; PRCA, pure red cell aplasia.
§During maintenance phase or the follow-up period; one patient discontinued study treatment.3
Comparable rates of AE-related discontinuation to CP alone
Both regimens generally well tolerated, with comparable rates of AE-related discontinuation to CP aline (ITT data)1
24.4% patients on IMFINZI® + LYNPARZA® discontinued treatment due to AEs (vs 18.6% on CP alone)
20.9% patients on IMFINZI® discontinued treatment due to AEs (vs 18.6% on CP alone)
Please refer to the SmPC for further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.
CP: Carboplatin & Paclitaxel, arEC: advanced and recurrent endometrial cancer, d/pMMR: deficient/proficient mismatch repair, mPFS: median progression free survival, HR: Hazard Ratio, AE: adverse event, ORR: Objective response rate, HRR: homologous recombination repair, ITT: intention to treat
GB-68805 | DOP: September 2025
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
